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Cutaneous adverse drug reactions 
caused by FDCAs – we need to 
characterise and manage them 
urgently
To the Editor: In April 2013, South Africa’s Minister of Health 
launched fixed-dose once-a-day combination antiretrovirals 
(FDCAs) comprising emtricitabine, efavirenz and tenofovir 
(Odimune and Tribuss). During the months following the 
introduction of these drugs, anecdotal reports from clinicians and 
patients are emerging of cutaneous adverse drug reactions (CADRs) 
associated with them. We have recently described the clinical 
characteristics of efavirenz-associated CADRs.[1] Efavirenz is a 
constituent of the FDCAs, so we have been actively surveying and 
documenting suspected FDCA-associated CADRs at Groote Schuur 
Hospital in Cape Town, South Africa.
Between 1 May and 31 August 2013, 7 patients with suspected 
FDCA-related CADRs presented to Groote Schuur Hospital. We 
used the Naranjo score, a validated scoring system, to assess the 
likelihood of the FDCA being the offending drug. The score is based 
on the pattern of response, the temporal relationship with the drug, 
withdrawal of the drug, rechallenge with the drug, alternative causes, 
the placebo response, drug levels in body fluids or tissues, the dose-
response relationship, previous patient experience with the drug, and 
confirmation by objective evidence.[2] Of the 7 cases, 1 was definitely a 
CADR associated with the FDCA based on the Naranjo score, 4 were 
probable cases and 2 were doubtful. The demographic and clinical 
characteristics of the definite and probable cases are summarised 
in Table 1. The clinical features were similar to those we described 
for efavirenz-associated CADRs.[1] All were of moderate severity 
according to the Common Terminology Criteria for Adverse Events.[3]
Because of their ease of use and the consequent improvement 
in patient compliance, the South African Department of Health 
expects to initiate 180 000 HIV-infected people on the FDCAs. 
Understanding the side-effect profile so that problems can be 
managed early on should help clinicians make informed decisions 
timeously and preserve the reputation of these important drugs in 
the fight against the HIV pandemic. Large prospective studies are 
needed urgently to characterise reactions associated with the FDCAs, 
identify the offending constituent(s) of the combinations, ascertain 
whether the reactions are severe enough to warrant interruption or 
termination of therapy, and develop management strategies if the 
FDCAs are terminated.
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Table 1. Demographic and clinical characteristics of 5 patients with definite or probable cutaneous adverse reactions to fixed-dose 
once-a-day combination antiretroviral drugs 
Case
Age 
(years) Gender
Duration of 
exposure before 
reaction (days)
Tender 
palmar 
erythema
Annular 
erythema
Photo-
distributed Fever Hepatitis Eosinophilia
Naranjo 
grade
1 27 F 14 Yes No No Yes Yes No Probable
2 38 M 11 Yes Yes Yes Yes Yes No Definite
3 39 F 6 Yes Yes Yes No No No Probable
4 40 F 31 Yes Yes Yes No No Yes Probable
5 64 F 2 Yes No No No No No Probable
F = female; M = male.
